Skip to main content

What the FDA labels say about taking them together

Alprazolam and fosaprepitant

Fosaprepitant's FDA label of July 29, 2026 names alprazolam in its drug interactions section; the alprazolam labels PlainMeds reads (2) do not name fosaprepitant. The fosaprepitant label: “Clinical Impact; Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions.”

Check it at the source: the alprazolam FDA label on DailyMed (effective January 18, 2023, PHARMACIA & UPJOHN COMPANY LLC); the fosaprepitant FDA label on DailyMed (effective July 29, 2026, AVYXA Pharma, LLC).

What does the alprazolam label say about fosaprepitant?

Alprazolam's label (effective January 18, 2023) and its 1 other brand-application label do not name fosaprepitant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Xanax), PHARMACIA & UPJOHN COMPANY LLC, effective January 18, 2023 (SPL set 388e249d-b9b6-44c3-9f8f-880eced0239f), via openFDA; the full label on DailyMed

What does the fosaprepitant label say about alprazolam?

Fosaprepitant label, drug interactions

Clinical Impact; Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see ].

Source: FDA drug label (Focinvez, NDA216686), Steriscience Specialties Private Limited, effective March 30, 2026 (SPL set 18a60093-cec8-1b8c-e063-6394a90a8902), via openFDA

Source: FDA drug label (NAVITRUX), AVYXA Pharma, LLC, effective July 29, 2026 (SPL set a41b7c3a-1376-43a7-b5b9-6ba2eba1e169), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

30Alprazolam generic labelers
16Fosaprepitant generic labelers
AlprazolamFosaprepitant
Labeled forAnxietyn/a
Boxed warningYesNo
Pharmacy cost (NADAC)$0.0236 per tablet 0.25 mg tabletn/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?